rheumatoid arthriitis Archives -

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price

AbbVie prices Rinvoq close to Humira after arthritis approval

https://pharmaphorum.com/news/abbvie-prices-upadacitinib-close-to-humira-after-arthritis-approval/

Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase

Mycenax’s Actemra biosimilar edges closer to approval

https://pharmaphorum.com/news/mycenaxs-actemra-biosimilar-edges-closer-to-approval/

Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of

RA pill setback spoils Lilly’s growth story

https://pharmaphorum.com/news/ra-pill-setback-spoils-lillys-growth-story/

Upadacitinib hopes drug will reduce reliance on Humira.

AbbVie looks beyond Humira as RA pill meets phase 3 targets

https://pharmaphorum.com/news/abbvie-looks-beyond-humira-ra-pill-meets-phase-3-targets/

rheumatoid arthriitis